CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer

MT Newswires Live05-15

CG Oncology (CGON) reported Friday initial results from a phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk, non-muscle invasive bladder cancer.

The biopharmaceutical company said the data "demonstrate encouraging high-grade event-free survival, high complete response rates, and a well-tolerated safety profile."

CG Oncology will present the data Saturday at the 2026 American Urological Association annual meeting in Washington, DC.

"As the first prospective intravesical-only combination study of its kind, these early data demonstrate robust clinical activity across both treatment schedules, a favorable safety profile, and comparable efficacy," Chief Medical Officer Vijay Kasturi said in a statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635308240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635308240","market":"nz","top_or_hot":-1,"title":"CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGON\">CG Oncology</a> (CGON) reported Friday initial results from a phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk, non-muscle invasive bladder cancer.</p><p>The biopharmaceutical company said the data \"demonstrate encouraging high-grade event-free survival, high complete response rates, and a well-tolerated safety profile.\"</p><p>CG Oncology will present the data Saturday at the 2026 American Urological Association annual meeting in Washington, DC.</p><p>\"As the first prospective intravesical-only combination study of its kind, these early data demonstrate robust clinical activity across both treatment schedules, a favorable safety profile, and comparable efficacy,\" Chief Medical Officer Vijay Kasturi said in a statement.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-15 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGON\">CG Oncology</a> (CGON) reported Friday initial results from a phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk, non-muscle invasive bladder cancer.</p><p>The biopharmaceutical company said the data \"demonstrate encouraging high-grade event-free survival, high complete response rates, and a well-tolerated safety profile.\"</p><p>CG Oncology will present the data Saturday at the 2026 American Urological Association annual meeting in Washington, DC.</p><p>\"As the first prospective intravesical-only combination study of its kind, these early data demonstrate robust clinical activity across both treatment schedules, a favorable safety profile, and comparable efficacy,\" Chief Medical Officer Vijay Kasturi said in a statement.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGON","symbol_name":"CG Oncology Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635308240","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635308240","pubTimestamp":1778849429,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CG Oncology  reported Friday initial results from a phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk, non-muscle invasive bladder cancer.The biopharmaceutical company said the data \"demonstrate encouraging high-grade event-free survival, high complete response rates, and a well-tolerated safety profile.\"CG Oncology will present the data Saturday at the 2026 American Urological Association annual meeting in Washington, DC.\"As the first prospective intravesical-only combination study of its kind, these early data demonstrate robust clinical activity across both treatment schedules, a favorable safety profile, and comparable efficacy,\" Chief Medical Officer Vijay Kasturi said in a statement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGON":"CG Oncology Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","CG":"凯雷","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4135":"资产管理与托管银行","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"CG Oncology报告了膀胱内联合疗法治疗膀胱癌研究的“令人鼓舞”数据","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CG":1.5,"CGON":1.5},"content_text":"CG Oncology (CGON) reported Friday initial results from a phase 2 study evaluating intravesical cretostimogene grenadenorepvec in combination with gemcitabine sequential versus concurrent treatment schedules in patients with high-risk, non-muscle invasive bladder cancer.The biopharmaceutical company said the data \"demonstrate encouraging high-grade event-free survival, high complete response rates, and a well-tolerated safety profile.\"CG Oncology will present the data Saturday at the 2026 American Urological Association annual meeting in Washington, DC.\"As the first prospective intravesical-only combination study of its kind, these early data demonstrate robust clinical activity across both treatment schedules, a favorable safety profile, and comparable efficacy,\" Chief Medical Officer Vijay Kasturi said in a statement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635308240","isCrawlerRequest":true}